WuXi AppTec stock: Morgan Stanley keeps HKD 207.40 target for WuXi AppTec stock

Published on 10/16/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 27, 2026. WuXi AppTec stock costs EUR 22.22 on October 16, 2026, up 1.05 percent versus the Tradegate close.

Target and results timeline

Morgan Stanley kept the HKD 207.40 H-share target on October 15, 2026.
WuXi AppTec is due to report on October 27, 2026, with HKD 18.10 billion revenue expected.
WuXi AppTec stock costs EUR 22.22 at Lang & Schwarz on October 16, 2026 at 5:00 p.m. CEST, 1.05 percent above the Tradegate close of October 16, 2026.
WuXi AppTec had a P/E ratio of 19.40 and a CNY 356.9 billion market capitalization on October 16, 2026.

WuXi AppTec, CNE100003F19, Illustration mit AI erstellt.

Morgan Stanley kept its Overweight rating and the HKD 207.40 target for WuXi AppTec's H shares on October 15, 2026, while its report based the A-share valuation on a CNY 200.00 target. That A-share target stood 38.60 percent above WuXi AppTec's CNY 144.30 Shanghai price on October 16, 2026. At Lang & Schwarz, WuXi AppTec was EUR 22.22 on October 16, 2026 at 5:00 p.m. CEST, up 1.05 percent versus the Tradegate close of October 16, 2026 (EUR 21.99).

Target distance reaches 38.60 percent

The Morgan Stanley report linked the target to planned capacity expansion at WuXi STA in Changzhou. The project is expected to add 800 tons of active pharmaceutical ingredient capacity and involves RMB 10.1 billion of investment, according to Sina Finance on October 15, 2026.

The same report said WuXi AppTec plans to lift small-molecule reactor capacity 25.00 percent from 4,000 to 5,000 cubic meters in 2026. Solid-phase peptide synthesis capacity was planned to rise 30.00 percent from 100,000 liters to 130,000 liters. The report also listed 2026 capital expenditure guidance of RMB 7.5 billion to RMB 8.5 billion.

October 27 results carry estimates

WuXi AppTec is due to report results for the quarter ended September 30, 2026, on October 27, 2026. finanzen.ch reported that two analysts expected HKD 18.10 billion of revenue, up 37.55 percent from HKD 13.16 billion in the year-earlier quarter. Three analysts expected earnings per share of HKD 2.97, compared with HKD 1.35 a year earlier.

Price range and yearly return

The Shanghai-listed stock closed at CNY 144.30 on October 16, 2026, down 6.60 percent from the previous session. Its CNY 87.09 to CNY 173.60 52-week range put the close 16.89 percent below the high. WuXi AppTec's year-to-date gain was 105.51 percent on the Tradegate market data page dated October 16, 2026, while the Lang & Schwarz quote was in after-hours trading.

Peer valuations on October 16

WuXi AppTec (Shanghai Stock Exchange, CNY): up 1.05 percent, P/E 19.40, market capitalization CNY 356.9 billion
Pharmaron Beijing (Shenzhen Stock Exchange, CNY): minus 6.81 percent, P/E 37.52, market capitalization CNY 53.8 billion
Asymchem Laboratories (Shenzhen Stock Exchange, CNY): minus 6.17 percent, P/E 51.41, market capitalization CNY 49.6 billion

Business scale supports the valuation

WuXi AppTec operates a contract research, development and manufacturing platform for pharmaceutical and life sciences companies across Asia, Europe and North America. The company says its services cover research, development, testing and manufacturing through an integrated CRDMO model.

Price holds above the Tradegate close

At EUR 22.22, the Lang & Schwarz quote stood above the EUR 21.99 Tradegate close for October 16, 2026. The next scheduled company date is the October 27, 2026 quarterly report, while the analyst target remains a separate valuation reference in HKD and CNY.

The further course of trading is shown by the continuously updated real-time quote of WuXi AppTec stock.